Volume 13 Issue 5, December 2019

By harvesting stem cells from umbilical cord blood and differentiating them into natural killer cells, Glycostem has developed oNKord, an affordable off-the-shelf cell therapy product indicated for oncology therapies that is ready to ship worldwide within 48 hours.

NeuroBo Pharmaceuticals has a phase 3-ready drug candidate, NB-01, in development for painful diabetic neuropathy and a number of other indications, as well as an investigational new drug (IND)-ready candidate, NB-02, that targets Alzheimer’s disease and tauopathies.

enGene has developed a proprietary nonviral gene delivery platform and Gene Pill technology to deliver orally administered gene therapies to mucosal tissues, creating new opportunities for treating hard-to-reach tissues across many indications.

The complement pathway’s intricate network of proteins, which have a key role in the innate immune system, are attracting dealmakers’ attention as targets for a variety of inflammatory diseases.

Avectas is developing Solupure, a next-generation cell-engineering tool for ex vivo immune cell therapy.

Noveome Biotherapeutics, Inc. is developing a new class of biologic consisting of the secretome of a novel population of cells derived from the amnion. Presently, the company is looking for partners to drive clinical drug development of its lead product, ST266, in ophthalmological indications.

With its lead candidate, ATH3G10, a first-in-class antibody indicated for large ST-elevation myocardial infarction (STEMI), Athera Biotechnologies is harnessing the process of efferocytosis to treat a range of vascular diseases.

Inotrem is developing novel immunomodulators that target the TREM-1 pathway. The company’s lead compound, nangibotide, is a first-in-class anti-TREM-1 peptide and is currently in phase 2 trials for septic shock.